DataMeds AI licenses US rights to Reboot Health AI's GLP-1 weight management platform

• DataMeds AI entered an exclusive licensing, revenue-sharing and marketing agreement with Reboot Health AI for U.S. direct-to-consumer rights to its care-management platform.
• The partners plan to integrate Reboot’s technology into the Health Lives Here app for patients taking GLP-1 medications.
• Weight-management support modules will be offered through monthly subscriptions, with related revenue shared between the partners.
• Development and pilot programs are planned before commercial launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610140948ACCESSWRNAPR_____1236761) on October 14, 2026, and is solely responsible for the information contained therein.